Precursor Cell Lymphoblastic Leukemia-lymphoma Clinical Trial
Official title:
Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refractory Acute Lymphoblastic Leukemia, With or Without Extramedullary Disease, or Relapsed or Refractory Lymphoblastic Lymphoma
Verified date | September 2020 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), safety and toxicity, and pharmacokinetics (PK) of ixazomib administered intravenously in combination with multiagent reinduction chemotherapy in pediatric participants with relapsed/refractory ALL or LLy.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | August 30, 2022 |
Est. primary completion date | August 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 17 Years |
Eligibility |
Inclusion Criteria: 1. Diagnosis of relapsed/refractory ALL with or without extramedullary disease, including central nervous system (CNS)2 (<5 white blood cell [WBC]/mcL] in the cerebrospinal fluid [CSF] with blasts) and CNS3 (>=5 WBC/mcL in the CSF with blasts), or relapsed/refractory LLy. Participants with mixed-phenotype ALL or mature (Burkitt-like) leukemia are excluded. 2. Relapsed/refractory ALL must have >=5% blasts in the bone marrow by morphology. 3. Relapsed/refractory LLy participants must have measurable disease documented by clinical, radiologic, and histologic criteria. 4. A Karnofsky performance status of >=50% (for participants aged >16 years) and a Lansky performance status of >=50% (for participants aged <=16 years). 5. Adequate organ function. 6. Failure of 1 or more therapeutic attempts. 7. Full recovery from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy before entering this study, as follows: - Cytoreduction with hydroxyurea: Hydroxyurea can be initiated and continued for up to 24 hours before the start of protocol therapy. - Cytotoxic therapy: At least 14 days must have elapsed since the completion of the last dose of chemotherapy, except intrathecal (IT) chemotherapy and/or maintenance therapy, such as vincristine (VCR), mercaptopurine, methotrexate, or glucocorticoids. There is no waiting period for those relapsing on maintenance therapy. - Hematopoietic stem cell transplantation (HSCT): Participants who have relapsed after HSCT are eligible, provided they have no evidence of acute or chronic graft-versus-host disease (GVHD), are not receiving GVHD prophylaxis or treatment, and are at least 90 days posttransplant at the time of enrollment. - Hematopoietic growth factors: At least 7 days must have elapsed since the completion of therapy with granulocyte colony-stimulating factor (G-CSF) or other growth factor at the time of enrollment. At least 14 days must have elapsed since the completion of therapy with pegfilgrastim. - Biologic (antineoplastic agent): At least 7 days must have elapsed since the last dose of a biologic agent. For agents that have known adverse events (AEs) occurring beyond 7 days after the end of administration, this period must be extended beyond the time during which AE are known to occur. The duration of this interval must be approved by the project clinician (or designee). - Monoclonal antibodies: At least 3 half-lives must have elapsed after the last dose of an administered monoclonal antibody. - Immunotherapy: At least 30 days must have elapsed after the completion of any type of immunotherapy (example, tumor vaccines, chimeric antigen receptor T-cells). - Photon radiotherapy (XRT): Craniospinal XRT is prohibited during protocol therapy. No washout period is necessary for radiation given to any extramedullary site other than the CNS; >=90 days must have elapsed if prior total body irradiation or craniospinal XRT was given. - Anthracyclines: Participants must have had a lifetime exposure of <400 mg/m^2 of doxorubicin equivalents of anthracyclines. - Proteasome inhibitors: Participants with a prior exposure to proteasome inhibitor (PIs) (example, bortezomib, carfilzomib) are eligible as long as the participant demonstrated at least a partial response to chemotherapy with a PI. Exclusion criteria: 1. ALL participants: have isolated extramedullary disease, including CNS or testicular disease. 2. Have Grade >=2 peripheral sensory or motor neuropathy, defined by the Modified "Balis" Pediatric Scale of Pediatric Neuropathies, at the time of enrollment. 3. Have a planned administration of chemotherapy, radiation therapy, or immunotherapy, other than the study drugs used for this protocol. 4. Have deoxyribonucleic acid fragility syndromes (example, Fanconi anemia, Bloom syndrome). 5. Have Down syndrome. 6. Are receiving cyclosporine, tacrolimus, or other agents to prevent graft-versus host disease (GVHD) after HSCT. 7. Have Philadelphia chromosome (Ph)-positive ALL or Ph-like ALL and are currently receiving tyrosine kinase inhibitor therapy. 8. Are receiving systemic treatment with strong inducers of cytochrome P450 3A (CYP3A)(example,rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, St. John's wort) within 14 days before study enrollment. 9. Are receiving systemic treatment with strong CYP3A inhibitors within 14 days before study enrollment. 10. Are receiving systemic treatment with inhibitors or inducers of P-glycoprotein (P-gp) within 14 days before study enrollment. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario Vall d'Hebron - PPDS | Barcelona | |
Spain | C.H. Regional Reina Sofia | Cordoba | |
Spain | Hospital Universitario La Paz | Madrid | |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | St Jude Children's Research Hospital | Memphis | Tennessee |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Millennium Pharmaceuticals, Inc. |
United States, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with Dose-limiting Toxicities (DLT) During Reinduction Chemotherapy | DLT: Grade 4 nonhematologic toxicity after first dose of ixazomib and is probably/definitely attributable to the ixazomib treatment regimen, with exceptions, example fever/infection with/without hospitalization, fatigue and gastrointestinal symptoms, hypofibrinogenemia, metabolic/laboratory abnormalities that resolve to less than or equal to(<=)Grade 2 within 7 days. Any Grade 3/4 nonhematologic toxicity after first dose of ixazomib that is possibly/probably/definitely attributable to the ixazomib treatment regimen and results in omission of subsequent dose of chemotherapy, with exception of fever/infection. Hematologic toxicities: Failure to recover a peripheral absolute neutrophil count (ANC) =0.5*10^9 per liter (/L) and a platelet count =50*10^9/L due to documented bone marrow hypoplasia (cellularity <10 20%) within 42 days after the beginning of systemic chemotherapy without evidence of active disease by bone marrow evaluation or active infection. | Up to Day 29 | |
Primary | Number of Participants With Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs) Based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Up to 30 months | ||
Primary | Number of Participants With Worst Shift From Baseline Values to Post-baseline Values in Clinical Laboratory Parameters | Up to 30 months | ||
Primary | AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for Ixazomib | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose and Day 11 pre-dose and at multiple time points (up to 264 hours) post-dose | ||
Primary | Cmax: Maximum Observed Plasma Concentration for Ixazomib | Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose and Day 11 pre-dose and at multiple time points (up to 264 hours) post-dose | ||
Secondary | Overall Response Rate (ORR) | ORR is defined as the percentage of participants with complete response (CR) or CR with incomplete platelet recovery (CRp) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR is defined as bone marrow with less than 5 percent (%) blast by morphology, no evidence of circulating blasts or extramedullary disease, and recovery of peripheral counts (ANC >=1.0*10^9/L and a platelet count >=100*10^9/L). CRp is defined as bone marrow with <5% blasts by morphology, no evidence of circulating blasts or extramedullary disease, and recovery of ANC (>1000/mcL) but insufficient recovery of platelets (counts <100, 000/mcL). | Up to 30 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05026229 -
A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL
|
N/A | |
Recruiting |
NCT05024357 -
A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL
|
N/A | |
Completed |
NCT03545659 -
Childhood Acute Lymphoblastic Leukaemia: Follow-Up
|
||
Completed |
NCT03985826 -
Health Care Utilisation Among Survivors of Childhood Acute Lymphoblastic Leukaemia
|
||
Recruiting |
NCT05660473 -
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
|
Phase 2 | |
Completed |
NCT03743246 -
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05968963 -
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
|
N/A | |
Active, not recruiting |
NCT01429610 -
Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia
|
Phase 2 | |
Completed |
NCT03384654 -
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
|
Phase 2 | |
Completed |
NCT01317940 -
Nutrition and Body Composition in Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02454270 -
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
|
Phase 1 | |
Completed |
NCT01331590 -
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia
|
Phase 0 | |
Completed |
NCT04456959 -
InO - A Retrospective Study of UK Patients With Leukaemia
|
||
Recruiting |
NCT03462095 -
De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)
|
N/A | |
Completed |
NCT01386619 -
NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03985215 -
The Value of Follow-Up After Childhood Acute Lymphoblastic Leukaemia in Denmark - Family Perspectives
|
||
Recruiting |
NCT02328950 -
A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome
|
N/A | |
Withdrawn |
NCT02973191 -
A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT05873322 -
Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma
|
||
Recruiting |
NCT02390752 -
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
|
Phase 1 |